脂肪生成
脂肪变性
内科学
内分泌学
胰岛素抵抗
化学
PI3K/AKT/mTOR通路
蛋白激酶B
脂肪肝
胰岛素受体
胰岛素
信号转导
生物
生物化学
脂肪组织
医学
疾病
作者
Cheng Cheng,Xiao-Huan Liu,Jing He,Jing Xing Gao,Jinting Zhou,Jing‐Na Fan,Xi Jin,Jianbo Zhang,Liao Chang,Zijun Xiong,Jun Myoung Yu,Shengbin Li,Xiaoming Li
标识
DOI:10.1002/mnfr.202101034
摘要
SCOPE: Hepatic steatosis and insulin resistance (IR) are risk factors for many metabolic syndromes such as NAFLD and T2DM. ApoA4 improves glucose hemostasis by increasing glucose-stimulated insulin secretion and glucose uptake via PI3K-Akt activation in adipocytes. However, whether ApoA4 has an effect on hepatic steatosis or IR remains unclear. METHODS AND RESULTS: ApoA4-knockout (KO) aggravates diet-induced obesity, hepatic steatosis, and IR in mice promoted by increased hepatic lipogenesis gene expression based on RNA-seq data. Conversely, liver-specific overexpression of ApoA4 via AAV-ApoA4 transduction reverses the effect in ApoA4-KO mice, accompanied by suppressed hepatic lipogenesis, increased lipolysis, and fatty acid oxidation. Short-term treatment with recombinant ApoA4 protein improves glucose clearance and liver insulin sensitivity, and reduces hepatic lipogenesis gene expression in the absence of insulin. Moreover, in primary hepatocytes and a hepatic cell line, ApoA4 improves hepatic glucose uptake via IRS-PI3K-Akt signaling and decreases fat deposition and hepatic lipogenesis gene expression by inhibiting SREBF1 activity. CONCLUSION: ApoA4 restricts hepatic steatosis by inhibiting SREBF1-mediated lipogenesis and improves insulin sensitivity and glucose uptake via IRS-PI3K-Akt signaling in the liver. These findings indicate that ApoA4 may serve as a therapeutic target for obesity-associated NAFLD.
科研通智能强力驱动
Strongly Powered by AbleSci AI